Next generation sequencing of glioblastoma circulating tumor cells: non-invasive solution for disease monitoring.
CTCs
culturing
gene expression
glioblastoma
in vitro
liquid biopsy
metacell
sequencing
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2021
2021
Historique:
received:
01
12
2019
accepted:
26
06
2020
entrez:
21
6
2021
pubmed:
22
6
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Treatment of aggressive glioblastoma multiforme (GBM) must be based on very precise histological and molecular diagnostic of GBM type. According to the WHO guidelines, only tissue biopsy is a relevant source of cellular material evaluated in the diagnostic process to specify the tumor features. Nevertheless, obtaining a GBM biopsy is complicated and relies mostly on resection surgery. Evaluating circulating free DNA and/or circulating tumor cells (CTCs) in the clinic, using a liquid biopsy could represent a non-invasive cancer care optimization. In the present study, the peripheral blood of patients undergoing GBM resection (n = 18) was collected and examined for CTCs. The feasibility of GBM molecular diagnostics from a simple non-invasive peripheral blood withdrawal was evaluated. The size-based enriched CTCs were analyzed using cytomorphology and their origin confirmed based on mutational analysis. In addition, shared DNA mutations in CTCs and in primary tumor tissue were searched. For the identification of CTCs, next generation sequencing (NGS) was used. The GeneReader™ sequencing platform enables targeted sequencing of a 12-gene panel and direct evaluation of detected gene variations using QIAGEN Clinical Insight Analyze (QCI-A) software with a special algorithm for liquid biopsy sequencing analysis. Herein, we present a standard operating procedure for CTC enrichment in GBM patients, CTC
Types de publication
Journal Article
Langues
eng
Pagination
4489-4499Informations de copyright
AJTR Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
J Neurooncol. 2009 Aug;94(1):97-101
pubmed: 19221865
Cancer Res. 2014 Apr 15;74(8):2152-9
pubmed: 24525740
Cancer Discov. 2014 Nov;4(11):1299-309
pubmed: 25139148
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14
pubmed: 23412337
Stem Cell Res Ther. 2013 Feb 28;4(1):18
pubmed: 23510696
Sci Transl Med. 2014 Jul 30;6(247):247ra101
pubmed: 25080476
J Mol Diagn. 2017 Jan;19(1):4-23
pubmed: 27993330
J Neurosurg Spine. 2012 Nov;17(5):438-48
pubmed: 22958073
Cancer. 1969 Aug;24(2):270-6
pubmed: 4307749
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Cancer Res. 2008 Oct 1;14(19):6302-9
pubmed: 18829513
Cytotechnology. 2016 Aug;68(4):1095-102
pubmed: 25862542
Mayo Clin Proc. 2007 Oct;82(10):1271-86
pubmed: 17908533
Am J Cancer Res. 2016 May 01;6(5):973-80
pubmed: 27293992
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Cancer. 2008 Jul 15;113(2):405-10
pubmed: 18484594
J Clin Oncol. 2008 Jun 20;26(18):3015-24
pubmed: 18565887
N Engl J Med. 1996 Sep 19;335(12):865-75
pubmed: 8778606
Int J Clin Exp Pathol. 2014 Sep 15;7(10):7164-71
pubmed: 25400813
Am J Cancer Res. 2015 Oct 15;5(11):3363-75
pubmed: 26807317
JAMA. 2017 Dec 19;318(23):2306-2316
pubmed: 29260225
Neuro Oncol. 2010 Jan;12(1):49-57
pubmed: 20150367